These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. The role of alendronate in mitigating perimenopausal bone loss: a double-blind randomized controlled pilot study. Mersereau JE; Khouri C; Jaffe RB Fertil Steril; 2010 Aug; 94(3):1138-40. PubMed ID: 20056199 [TBL] [Abstract][Full Text] [Related]
5. Effects of alendronate on bone quality and remodeling in glucocorticoid-induced osteoporosis: a histomorphometric analysis of transiliac biopsies. Chavassieux PM; Arlot ME; Roux JP; Portero N; Daifotis A; Yates AJ; Hamdy NA; Malice MP; Freedholm D; Meunier PJ J Bone Miner Res; 2000 Apr; 15(4):754-62. PubMed ID: 10780867 [TBL] [Abstract][Full Text] [Related]
6. Age-related changes in marmoset trabecular and cortical bone and response to alendronate therapy resemble human bone physiology and architecture. Bagi CM; Volberg M; Moalli M; Shen V; Olson E; Hanson N; Berryman E; Andresen CJ Anat Rec (Hoboken); 2007 Aug; 290(8):1005-16. PubMed ID: 17610276 [TBL] [Abstract][Full Text] [Related]
11. Drug injury in the upper gastrointestinal tract: effects of alendronate. Khapra AP; Rose S Gastrointest Endosc Clin N Am; 2006 Jan; 16(1):99-110. PubMed ID: 16546026 [TBL] [Abstract][Full Text] [Related]
12. Alendronate for the prevention and treatment of glucocorticoid-induced osteoporosis. Glucocorticoid-Induced Osteoporosis Intervention Study Group. Saag KG; Emkey R; Schnitzer TJ; Brown JP; Hawkins F; Goemaere S; Thamsborg G; Liberman UA; Delmas PD; Malice MP; Czachur M; Daifotis AG N Engl J Med; 1998 Jul; 339(5):292-9. PubMed ID: 9682041 [TBL] [Abstract][Full Text] [Related]
13. Decimal point--osteoporosis therapy at the 10-year mark. Strewler GJ N Engl J Med; 2004 Mar; 350(12):1172-4. PubMed ID: 15028820 [No Abstract] [Full Text] [Related]
14. [Parathyroid and bone. Evidence and perspective of parathyroid therapy for patients with osteoporosis]. Wada S; Fukawa T; Kamiya S Clin Calcium; 2007 Dec; 17(12):1888-94. PubMed ID: 18057665 [TBL] [Abstract][Full Text] [Related]
16. Correlations between biochemical markers of bone turnover and bone density responses in patients with glucocorticoid-induced osteoporosis treated with teriparatide or alendronate. Burshell AL; Möricke R; Correa-Rotter R; Chen P; Warner MR; Dalsky GP; Taylor KA; Krege JH Bone; 2010 Apr; 46(4):935-9. PubMed ID: 20060081 [TBL] [Abstract][Full Text] [Related]
18. [New development in bisphosphonate treatment. When and how long should patients take bisphosphonates for osteoporosis?]. Yamaguchi T; Sugimoto T Clin Calcium; 2009 Jan; 19(1):38-43. PubMed ID: 19122263 [TBL] [Abstract][Full Text] [Related]
19. Effects of Short Term Alendronate Administration on Bone Mineral Density in Patients with Chronic Kidney Disease. Aggarwal HK; Jain D; Chhabra P; Yadav RK Pril (Makedon Akad Nauk Umet Odd Med Nauki); 2018 Jul; 39(1):5-13. PubMed ID: 30110263 [No Abstract] [Full Text] [Related]
20. A comparison of the effect of alendronate and risedronate on bone mineral density in postmenopausal women with osteoporosis: 24-month results from FACTS-International. Reid DM; Hosking D; Kendler D; Brandi ML; Wark JD; Marques-Neto JF; Weryha G; Verbruggen N; Hustad CM; Mahlis EM; Melton ME Int J Clin Pract; 2008 Apr; 62(4):575-84. PubMed ID: 18324951 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]